American Psychiatric Association Publishing is the world’s premier publisher of books, journals, and multimedia on psychiatry, mental health, and behavioural science. We offer authoritative, up-to-date, and affordable information geared toward psychiatrists, other mental health professionals, psychiatric residents, medical students, and the general public.
APA Publishing is a division of the American Psychiatric Association. Its purpose is twofold: to serve as the distributor of publications of the Association and to publish books independent of the policies and procedures of the American Psychiatric Association. APA Publishing has grown since its founding in 1981 into a full-service publishing house, including a staff of editorial, production, marketing, and business experts devoted to publishing for the field of psychiatry and mental health.
Finally-a definitive guide to womens reproductive mental health. The Textbook of Womens Reproductive Mental Health is the first comprehensive text for understanding, diagnosing, and supporting the unique mental health needs of women and others who undergo female reproductive transitions during their entire reproductive life cycle.
The Addiction Casebook consists of 13 clinical cases that exemplify DSM-5 addiction diagnoses commonly encountered in clinical practice. Written in an engaging, easy-to-understand manner, the book complements substance abuse textbooks by providing hands-on experience with real-life situations and updated information relating to DSM-5 (R) ......
This definitive history of the American Board of Psychiatry and Neurology (ABPN) shows how the Board, by defining core competencies in psychiatry and neurology, established national guidelines and standards for certification during an era of unparalleled technical and therapeutic advances.
This book provides an in-depth look at clinical and public health approaches to this epidemic from both psychiatric and medical perspectives and gives mental health professionals the big picture necessary to understand the epidemic.
The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD.
The lifetime prevalence of eating disorders in the United States is approximately 0.80% for anorexia nervosa, 0.28% for bulimia nervosa, and 0.85% for binge-eating disorder, although estimates can vary depending on the study location, sample demographic characteristics, case finding, and diagnostic approaches.
Focuses specifically on evidence-based pharmacological and non-pharmacological treatments for schizophrenia and includes statements related to assessment and treatment planning, which are an integral part of patient-centered care. It provides direction on implementing these recommendations into clinical practice.
The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.
